Method and apparatus for controlling anti-tachyarrhythmia pacing using hemodynamic sensor

• US 7,844,331 B2
• Filed: 12/20/2005
• Issued: 11/30/2010
• Est. Priority Date: 12/20/2005
• Status: Expired due to Fees

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Carlson, Gerrard M., Li, Dan, Hahn, Stephen J.
• Primary Examiner(s): Layno; Carl H
• Assistant Examiner(s): Behringer; Luther G
• Application Number:
  US11/312,082
• Publication Number:
  US 20070142866A1
• Time in Patent Office: 1,806 Days
• Field of Search: 600/486, 600/500, 600/510, 607/4, 607/17, 607/23, 607/50, 607 14- 15
• US Class Current: 607/14
• CPC Class Codes: A61N 1/3622 comprising two or more electrodes co-operating with different heart regions
• CPC Class Codes: A61N 1/36514 controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by two or more physical parameters A61N1/36585

Abstract

A cardiac rhythm management (CRM) system includes an implantable medical device that delivers anti-tachyarrhythmia therapies including anti-tachyarrhythmia pacing (ATP) and at least one hemodynamic sensor that senses a hemodynamic signal. When a tachyarrhythmia episode is detected, the CRM system analyzes the hemodynamic signal to determine whether and/or when to deliver an ATP. In one embodiment, a hemodynamic parameter extracted from the hemodynamic signal is used to predict the potential effectiveness of ATP in terminating the detected tachyarrhythmia episode. In another embodiment, a characteristic feature detected from the hemodynamic signal is used to determine an ATP window during which a delivery of ATP is initiated.

Claims

1. A cardiac rhythm management (CRM) system, comprising:

a sensing circuit to sense at least one cardiac signal;

a tachyarrhythmia detector, coupled to the sensing circuit, to detect a cardiac cycle length from the at least one cardiac signal and detect a tachyarrhythmia episode using the detected cardiac cycle length;

a hemodynamic sensor to sense a hemodynamic signal indicative of hemodynamic performance;

a hemodynamic parameter detector, coupled to the hemodynamic sensor, to detect a hemodynamic parameter from the hemodynamic signal;

a pacing circuit to deliver pacing pulses;

a therapy controller coupled to the tachyarrhythmia detector, the hemodynamic parameter detector, and the pacing circuit, the therapy controller including;

a therapy selector adapted to compare an arrhythmic value of the hemodynamic parameter detected during the detected tachyarrhythmia episode to a normal range of the hemodynamic parameter and to select an anti-tachyarrhythmia pacing (ATP) algorithm in response to the arrhythmic value of the hemodynamic parameter falling within the normal range of the hemodynamic parameter and a cardioversion/defibrillation algorithm in response to the arrhythmic value of the hemodynamic parameter falling out of the normal range of the hemodynamic parameter;

a characteristic feature detector adapted to detect a predetermined type morphological feature of the hemodynamic signal, the predetermined type morphological feature temporally associated with an aortic valve closure and a pulmonary valve closure; and

an ATP controller, coupled to the therapy selector and the characteristic feature detector, to control the delivery of the pacing pulses by executing the selected ATP algorithm, the ATP controller adapted to select the detected predetermined type morphological feature as a beginning point of an ATP window and initiate a delivery of a burst of the pacing pulses within the ATP window to interrupt a reentrant loop causing the tachyarrhythmia.

2. The CRM system of claim 1, further comprising:

a template generator to produce the normal range of the hemodynamic parameter, the template generator including;

an normal sinus rhythm (NSR) detector, coupled to the sensing circuit, to detect an NSR from the at least one cardiac signal; and

a normal range generator coupled to the NSR detector and the hemodynamic parameter detector, the normal range generator adapted to receive a plurality of NSR values of the hemodynamic parameter detected while the NSR is detected and to produce the normal range of the hemodynamic parameter based on the plurality of NSR values of the hemodynamic parameter; and

a template storage device, coupled to the normal range generator, to store the normal range of the hemodynamic parameter.

3. The CRM system of claim 2, wherein the normal range generator is adapted to produce the normal range using an equation:

|X|_AVG±

k·

|X|_SD, where |X|_AVG is an average value of the hemodynamic parameter calculated using the plurality of NSR values of the hemodynamic parameter, |X|_SD is a standard deviation of the hemodynamic parameter calculated using the plurality of NSR values of the hemodynamic parameter, and k is a predetermined constant.

4. The CRM system of claim 1, wherein the hemodynamic signal comprises a heart sound signal indicative of at least second heart sounds (S2), the hemodynamic parameter comprises an S2 amplitude, the hemodynamic sensor includes a heart sound sensor adapted to sense the heart sound signal, and the hemodynamic parameter detector comprises an amplitude detector to detect the S2 amplitude from the heart sound signal.

5. The CRM system of claim 1, wherein the hemodynamic signal comprises an arterial pressure signal, the hemodynamic parameter comprises an arterial pressure, the hemodynamic sensor comprises an arterial pressure sensor adapted to sense the arterial pressure signal, and the hemodynamic parameter detector comprises a pressure detector to detect the arterial pressure from the arterial pressure signal.

6. The CRM system of claim 1, wherein the hemodynamic signal comprises an impedance signal indicative of at least one of a thoracic impedance and a cardiac impedance, the hemodynamic parameter comprises an impedance, the hemodynamic sensor comprises an impedance sensor adapted to sense the impedance signal, and the hemodynamic parameter detector comprises an impedance detector to detect the impedance from the impedance signal.

7. A method for operating a cardiac rhythm management (CRM) device, the method comprising:

sensing at least one cardiac signal;

detecting a cardiac cycle length using the at least one cardiac signal;

detecting a tachyarrhythmia episode using the detected cardiac cycle length;

sensing a hemodynamic signal indicative of hemodynamic performance;

detecting a hemodynamic parameter from the hemodynamic signal;

producing an arrhythmic value of the hemodynamic parameter being a value of the hemodynamic parameter detected during the detected tachyarrhythmia episode;

comparing the arrhythmic value of the hemodynamic parameter to a normal range of the hemodynamic parameter;

selecting anti-tachyarrhythmia pacing (ATP) in response to the arrhythmic value of the hemodynamic parameter falling within the normal range of the hemodynamic parameter and a cardioversion/defibrillation algorithm in response to the arrhythmic value of the hemodynamic parameter falling out of the normal range of the hemodynamic parameter;

detecting a predetermined type morphological feature of the hemodynamic signal the predetermined type morphological feature temporally associated with an aortic valve closure and a pulmonary valve closure;

selecting the predetermined type morphological feature as a beginning point of an ATP window; and

initiating a delivery of a burst of ATP pulses within the ATP window to interrupt a reentrant loop causing the tachyarrhythmia.

8. The method of claim 7, further comprising:

detecting a normal sinus rhythm (NSR) from the at least one cardiac signal; and

producing the normal range of the hemodynamic parameter using a plurality of NSR values of the hemodynamic parameter each being a value of the hemodynamic parameter detected during the NSR.

9. The method of claim 8, wherein producing the normal range of the hemodynamic parameter comprises producing the normal range using an equation:

|X|_AVG±

k·

|X|_SD, where |X|_AVG is an average value of the hemodynamic parameter calculated using the plurality of NSR values of the hemodynamic parameter, |X|_SD is a standard deviation of the hemodynamic parameter calculated using the plurality of NSR values of the hemodynamic parameter, and k is a predetermined constant.

10. The method of claim 7, wherein sensing the hemodynamic signal comprises sensing a heart sound signal indicative of at least second heart sounds (S2), and detecting the hemodynamic parameter from the hemodynamic signal comprises detect an S2 amplitude from the heart sound signal.

11. The method of claim 7, wherein sensing the hemodynamic signal comprises sensing an arterial pressure signal, and detecting the hemodynamic parameter from the hemodynamic signal comprises detecting an arterial pressure from the arterial pressure signal.

12. The method of claim 7, wherein sensing the hemodynamic signal comprises sensing an impedance signal indicative of at least one of a thoracic impedance and a cardiac impedance, and detecting the hemodynamic parameter from the hemodynamic signal comprises detecting an impedance from the impedance signal.

13. A cardiac rhythm management (CRM) system, comprising:

a sensing circuit to sense at least one cardiac signal;

a tachyarrhythmia detector, coupled to the sensing circuit, to detect a tachyarrhythmia episode from the at least one cardiac signal;

a hemodynamic sensor to sense a hemodynamic signal indicative of hemodynamic performance;

a pacing circuit to deliver pacing pulses;

a therapy controller coupled to the tachyarrhythmia detector, the hemodynamic sensor, and the pacing circuit, the therapy controller including;

a characteristic feature detector adapted to detect a predetermined type characteristic feature of the hemodynamic signal, the predetermined type characteristic feature being a morphological feature temporally associated with an aortic valve closure and a pulmonary valve closure; and

an anti-tachyarrhythmia pacing (ATP) controller coupled to the characteristic feature detector, the ATP controller adapted to select the detected predetermined type morphological feature as a beginning point of an ATP window and initiate a delivery of a burst of the pacing pulses within the ATP window.

14. The CRM system of claim 13, wherein the hemodynamic signal comprises a heart sound signal indicative of at least second heart sounds (S2), the predetermined type characteristic feature comprises a peak of S2, the hemodynamic sensor includes a heart sound sensor adapted to sense the heart sound signal, and the characteristic feature detector comprises an S2 peak detector adapted to detect the peak of S2 from the heart sound signal.

15. The CRM system of claim 13, wherein the hemodynamic signal comprises an arterial pressure signal, the predetermined type characteristic feature comprises a dicrotic notch of the arterial pressure signal, the hemodynamic sensor comprises an arterial pressure sensor adapted to sense the arterial pressure signal, and the characteristic feature detector comprises a dicrotic notch detector adapted to detect the dicrotic notch.

16. The CRM system of claim 13, wherein the hemodynamic signal comprises an impedance signal (Z) indicative of at least one of a thoracic impedance and a cardiac impedance, the predetermined type characteristic features comprises a trough point of the first derivative of the impedance signal (dZ/dt), the hemodynamic sensor comprises an impedance sensor adapted to sense the impedance signal, and the characteristic feature detector is adapted to produce a signal being the first derivative of the impedance signal (dZ/dt) and to detect a trough point of the signal being the first derivative of the impedance signal (dZ/dt) in a cardiac cycle.

17. The CRM system of claim 13, wherein the hemodynamic signal comprises an impedance signal (Z) indicative of at least one of a thoracic impedance and a cardiac impedance, the predetermined type characteristic feature comprises a zero-crossing point of the second derivative of the impedance signal (d²Z/dt²), the hemodynamic sensor comprises an impedance sensor adapted to sense the impedance signal, and the characteristic feature detector is adapted to produce a signal being the second derivative of the impedance signal (d²Z/dt²) and to detect a zero-crossing point of the signal being the second derivative of the impedance signal (d²Z/dt²) in a cardiac cycle.

18. The CRM system of claim 13, wherein the ATP controller comprises an ATP window locator adapted to locate the beginning point of the ATP window;

and

an ATP timer, coupled to the ATP window locator, to time an ATP interval from the beginning point of the ATP window and initiate the delivery of the burst of the pacing pulses upon expiration of the ATP interval.

19. The CRM system of claim 18, wherein the therapy controller further comprises:

a hemodynamic parameter detector, coupled to the hemodynamic sensor, to detect a hemodynamic parameter from the hemodynamic signal; and

a therapy selector coupled to the hemodynamic parameter detector, the therapy selector adapted to compare an arrhythmic value of the hemodynamic parameter detected during the tachyarrhythmia episode to a normal range of the hemodynamic parameter and to select an ATP algorithm if the arrhythmic value of the hemodynamic parameter falls within the normal range of the hemodynamic parameter, and

wherein the ATP controller is adapted to control the delivery of the pacing pulses by executing the selected ATP algorithm.

20. A method for operating a cardiac rhythm management (CRM) device, the method comprising:

sensing at least one cardiac signal;

detecting a tachyarrhythmia episode from the at least one cardiac signal;

sensing a hemodynamic signal indicative of hemodynamic performance;

detecting a predetermined type characteristic feature of the hemodynamic signal, the predetermined type characteristic feature being a morphological feature temporally associated with an aortic valve closure and a pulmonary valve closure;

selecting the predetermined type morphological feature as a beginning point of an anti-tachyarrhythmia pacing (ATP) window; and

initiating a delivery of a burst of ATP pulses within the ATP window to interrupt a reentrant loop causing the tachyarrhythmia.

21. The method of claim 20, wherein initiating the delivery of the burst of ATP pulses comprises:

timing a predetermined ATP interval from the beginning point of the ATP window; and

initiating the delivery of ATP when the ATP interval expires.

22. The method of claim 21, wherein sensing the hemodynamic signal comprises sensing a heart sound signal indicative of at least second heart sounds (S2), and detecting the predetermined type characteristic feature from the hemodynamic signal comprises detecting a peak of S2 from the heart sound signal.

23. The method of claim 21, wherein sensing the hemodynamic signal comprises sensing an arterial pressure signal, and detecting the predetermined type characteristic feature from the hemodynamic signal comprises detecting a dicrotic notch from the arterial pressure signal.

24. The method of claim 21, wherein sensing the hemodynamic signal comprises sensing an impedance signal (Z) indicative of at least one of a thoracic impedance and a cardiac impedance, and detecting the predetermined type characteristic feature from the hemodynamic signal comprises:

producing a signal being the first derivative of the impedance signal (dZ/dt); and

detecting a trough point of the signal being the first derivative of the impedance signal (dZ/dt) in a cardiac cycle.

25. The method of claim 21, wherein sensing the hemodynamic signal comprises sensing an impedance signal (Z) indicative of at least one of a thoracic impedance and a cardiac impedance, and detecting the predetermined type characteristic feature from the hemodynamic signal comprises:

producing a signal being the second derivative of the impedance signal (d²Z/dt²); and

detecting a zero-crossing point of the signal being the second derivative of the impedance signal (d²Z/dt²) in a cardiac cycle.

26. The method of claim 21, further comprising:

detecting a hemodynamic parameter from the hemodynamic signal;

comparing an arrhythmic value of the hemodynamic parameter detected during the tachyarrhythmia episode to a normal range of the hemodynamic parameter; and

selecting an ATP algorithm if the arrhythmic value of the hemodynamic parameter falls within the normal range of the hemodynamic parameter, and

wherein timing the delivery of ATP using the beginning point of the ATP window comprises timing the delivery of ATP by executing the selected ATP algorithm using the beginning point of the ATP window.